US 10793855
Compositions for modulating expression of C9ORF72 antisense transcript
granted A61KA61K31/712A61K31/7125
Quick answer
US patent 10793855 (Compositions for modulating expression of C9ORF72 antisense transcript) held by Ionis Pharmaceuticals, Inc. expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61K, A61K31/712, A61K31/7125, A61K31/713, A61K45/06